Amgen 2010 Annual Report Download - page 108

such forfeiture, expiration or cash settlement, be used again for new grants under the 2009 Plan and the shares
subject to such awards will be added back to the pool of available shares under the 2009 Plan as (i) one (1) share
if such shares were subject to an option or stock appreciation right granted under the 2009 Plan and (ii) as
1.9 shares if such shares were subject to awards other than options or stock appreciation rights granted under
the 2009 Plan.
(2) This plan has terminated as to future grants. The number under column (a) with respect to this plan includes
approximately 13.95 million shares issuable upon the exercise of outstanding options with a weighted average
exercise price of approximately $57.69, approximately 2.45 million shares issuable upon the vesting of
outstanding restricted stock units and approximately 0.85 million shares issuable for outstanding performance
units granted in 2008 based on a target performance. The maximum that could be earned would be 200% of the
units granted in 2008.
(3) The purchases occurred on June 15, 2010 and December 15, 2010 (the “Purchase Dates”) with a purchase of
217,009 shares of Common Stock at a purchase price of $52.36 per shares on June 15, 2010 and 158,204 shares
of Common Stock at a purchase price of $52.89 per share on December 15, 2010. Such purchases reflect 95%
of the closing price of the Common Stock on the applicable Purchase Date.
(4) These plans have terminated as to future grants. These Plans were originally assumed pursuant to the terms of
the merger agreement between Amgen and Immunex which was approved by our stockholders in May 2002.
Both plans were previously approved by Immunex’s shareholders. The number under column (a) with respect
to the Amended and Restated 1999 Equity Incentive Plan includes approximately 11.64 million shares
issuable upon the exercise of outstanding options with a weighted average exercise price of approximately
$61.62 and approximately 27,000 shares issuable upon the vesting of outstanding restricted stock units.
(5) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with
the merger of Tularik with and into Amgen SF, LLC, a wholly owned subsidiary of Amgen, on August 13,
2004. This plan was previously approved by Tularik’s shareholders.
(6) This plan terminated as to future grants. The number under column (a) with respect to this plan includes
approximately 5.49 million shares issuable upon the exercise of outstanding options with a weighted average
exercise price of approximately $63.44 and approximately 132,000 shares issuable upon the vesting of
outstanding restricted stock units.
(7) These plans have terminated as to future grants. These plans were originally assumed by Amgen in connection
with the merger of Abgenix with and into Amgen Fremont Inc., a wholly owned subsidiary of Amgen, on
April 1, 2006. The Amended and Restated 1996 Incentive Stock Plan (1996 Plan) was previously approved by
Abgenix’s shareholders. The number under column (a) with respect to the 1996 Plan includes approximately
311,000 shares issuable upon the exercise of outstanding options with a weighted average exercise price of
approximately $68.81. The number under column (a) with respect to the Amended and Restated 1999
Incentive Stock Plan includes approximately 1.42 million shares issuable upon the exercise of outstanding
options with a weighted average exercise price of approximately $65.66 and approximately 259,000 shares
issuable upon the vesting of outstanding restricted stock units.
(8) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with
the merger of Avidia, Inc. with and into Amgen Mountain View Inc., a wholly owned subsidiary of Amgen, on
October 24, 2006.
Security Ownership of Directors and Executive Officers and Certain Beneficial Owners
Information about security ownership of certain beneficial owners and management is incorporated by
reference from the sections entitled “SECURITY OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS
and SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS” in our Proxy Statement.
92